ClinVar Miner

Submissions for variant NM_000059.3(BRCA2):c.426-20T>G (rs1064795008)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Color RCV000775862 SCV000910337 likely benign Hereditary cancer-predisposing syndrome 2017-04-13 criteria provided, single submitter clinical testing
GeneDx RCV000484138 SCV000570392 uncertain significance not provided 2016-05-17 criteria provided, single submitter clinical testing This variant is denoted BRCA2 c.426-20T>G or IVS4-20T>G and consists of a T>G nucleotide substitution at the -20 position of intron 4 of the BRCA2 gene. Using alternate nomenclature, this variant would be defined as BRCA2 654-20T>G. In silico splicing models are inconsistent. This variant has not, to our knowledge, been published in the literature as pathogenic or benign. BRCA2 c.426-20T>G was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. The thymine (T) nucleotide that is altered is not conserved across species. Based on currently available evidence, it is unclear whether BRCA2 c.426-20T>G is pathogenic or benign. We consider it to be a variant of uncertain significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.